← Back to search
ENTASIS THERAPEUTICS, INC.
WALTHAM, MA, 02451
Unclaimed
Prime contracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | TO IDENTIFY AND DEVELOP A NON-BETA-LACTAM PBP INHIBITOR (NBP) WITH BROAD SPECTRUM OF ACTIVITY AGAINST MDR GRAM-NEGATIVE ESKAPE PATHOGENS. | — | $5,604,274 | Aug 18, 2026 | Jul 1, 2020 – Dec 31, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THIS PROJECT SUPPORTS THE EARLY DEVELOPMENT OF ETX1791, A NEW INVESTIGATIONAL ANTIBIOTIC DESIGNED TO TREAT SERIOUS INFECTIONS CAUSED BY DRUG-RESISTANT GRAM-NEGATIVE BACTERIA. THESE INFECTIONS ARE A GROWING GLOBAL HEALTH THREAT AND ARE INCREASINGLY DIFFICULT TO TREAT WITH EXISTING MEDICINES. ETX1791 IS A DERIVATIVE OF ETX0462, A MOLECULE THAT HAS PREVIOUSLY SHOWN STRONG ACTIVITY AGAINST A BROAD RANGE OF CLINICALLY IMPORTANT GRAM-NEGATIVE BACTERIAL PATHOGENS. THE GOAL OF THE CURRENT PROGRAM IS TO ANSWER A FOCUSED SET OF KEY QUESTIONS NEEDED TO FURTHER CHARACTERIZE ETX1791 AND INFORM FUTURE DEVELOPMENT PLANNING. THIS WORK WILL GENERATE ESSENTIAL DATA ON ACTIVITY AGAINST CURRENT CLINICAL BACTERIAL STRAINS, EFFICACY IN ANIMAL MODELS OF INFECTION, AND POTENTIAL FOR CLINICAL DEVELOPMENT. THE PROGRAM INCLUDES SEVERAL COORDINATED ACTIVITIES TO: --CONFIRM THAT ETX1791 CAN BE PRODUCED AND HANDLED APPROPRIATELY FOR DEVELOPMENT. --EVALUATE ITS EFFECTIVENESS AGAINST A LARGE AND RECENT COLLECTION OF CLINICALLY RELEVANT BACTERIAL PATHOGENS. --UNDERSTAND HOW THE DRUG IS PROCESSED IN VIVO AND CONVERTED TO ITS ACTIVE FORM. --ASSESS WHETHER IT CAN BE GIVEN BOTH INTRAVENOUSLY AND AS AN ORAL TREATMENT, WHICH COULD ALLOW PATIENTS TO TRANSITION FROM HOSPITAL-BASED TO OUTPATIENT CARE. --IDENTIFY ANY EARLY SAFETY CONSIDERATIONS AND BETTER UNDERSTAND HOW THE DRUG IS CLEARED FROM THE BODY. THESE STUDIES ARE DESIGNED WITH CLEAR SUCCESS CRITERIA SO THAT DEVELOPMENT DECISIONS CAN BE MADE EFFICIENTLY. AT THE END OF THIS WORK, THE PROJECT WILL DELIVER A COMPREHENSIVE DATASET THAT HELPS DEFINE THE DRUG’S POTENTIAL USE, SUPPORTS ITS TARGET PRODUCT PROFILE, AND INFORMS NEXT STEPS FOR MORE ADVANCED PRECLINICAL AND CLINICAL EVALUATION. OVERALL, THIS PROGRAM AIMS TO ADVANCE A PROMISING NEW ANTIBIOTIC CANDIDATE THAT COULD ADDRESS URGENT UNMET MEDICAL NEEDS AND HELP COMBAT THE GROWING CHALLENGE OF ANTIBIOTIC RESISTANCE. KC4299 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $269,501 | Jul 17, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | PSEUDOMONAS AERUGINOSA AND ACINETOBACTER BAUMANNII ARE TWO OF THE MOST DANGEROUS MDR GRAM-NEGATIVE BACTERIAL PATHOGENS AND, IN 2013, THE CDC INCLUDED THEM IN THEIR LIST OF THE MOST SERIOUS PUBLIC HEALTH THREATS. RECENTLY, THE WHO ALSO CLASSIFIED THEM AS CRITICAL PATHOGENS TO TARGET FOR R&D EFFORTS. OF THE DIFFERENT CLASSES OF ANTIBIOTICS USED TO TREAT THESE SERIOUS INFECTIONS, BETA-LACTAMS HAVE HISTORICALLY BEEN THE AGENTS OF CHOICE GIVEN THEIR SAFETY AND IMPRESSIVE EFFICACY. BETA-LACTAMS WORK BY BINDING TO PENICILLIN-BINDING-PROTEINS (PBPS), IMPEDING THEIR ROLE IN CELL WALL SYNTHESIS THUS LEADING TO BACTERIAL CELL DEATH. IN RESPONSE TO THE USE OF THESE ANTIBIOTICS, BACTERIA HAVE EVOLVED TO PRODUCE BETA-LACTAMASES WHICH INACTIVATE BETA-LACTAMS. THIS HAS FORCED PHYSICIANS TO RESORT TO USING HIGHLY TOXIC AGENTS THAT OFTEN CREATE OTHER PATIENT COMPLICATIONS. ALTHOUGH PHARMACEUTICAL AND BIOTECH COMPANIES HAVE DEVELOPED BETA-LACTAMASE INHIBITORS TO RESTORE BETA-LACTAM EFFICACY, THEIR USE HAS NOT KEPT PACE WITH INCREASES IN THE CLINICAL PREVALENCE AND DIVERSITY OF BETA-LACTAMASES. ADDITIONAL ANTIBIOTIC AGENTS ARE NEEDED AND PBPS REMAIN VERY ATTRACTIVE THERAPEUTIC TARGETS BECAUSE THEY ARE UNIQUE TO BACTERIAL CELLS AND ESSENTIAL FOR SURVIVAL ACROSS GRAM-NEGATIVE BACTERIA. OUR PROGRAM IS BASED ON THE DISCOVERY OF NOVEL, COVALENT NON-BETA-LACTAM (NBL) PBP INHIBITORS WITH ACTIVITY AGAINST MDR P. AERUGINOSA THAT ARE NOT DEGRADED BY ANY OF THE BETA-LACTAMASES TESTED IN VITRO TO DATE. OUR CURRENT CANDIDATE, ETX0462, HAS DEMONSTRATED POTENT IN VITRO AND IN VIVO ANTIBIOTIC ACTIVITY AND IS CURRENTLY IN PRECLINICAL DEVELOPMENT. THE PROPOSED PROJECT PLAN IS TO ULTIMATELY DELIVER A NOVEL CLASS OF ANTIBIOTIC AGENT TO TREAT SERIOUS GRAM-NEGATIVE INFECTIONS. 4500004576 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $52,164 | Feb 2, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced